Dow Future Option Chain Free Gift Nifty Live X

Natco Pharma Rights Issue 2026 Details

Natco Pharma Rights Issue

The Natco Pharma Rights issue 2026 will be hit the October 12, 2026 and close on October 22, 2026. The company has set a record date of the rights issue on October 01, 2026. The company will offer 1,70,58,082 shares through this rights issue and the company will collect ₹1279.36 crores and the company price of this issue has been announced at ₹750 per share as per the face value of ₹2.

NATCO Pharma Limited is an India-based, research-driven and vertically integrated pharmaceutical company engaged in the development, manufacturing and marketing of finished dosage formulations (FDFs), active pharmaceutical ingredients (APIs) and agrochemical products. Founded in 1981, the company has developed a strong presence in niche and complex pharmaceutical products, with a particular focus on oncology and other specialty therapies.

The company operates across two major business segments Pharmaceuticals and Agrochemicals. Its pharmaceutical business includes domestic and international formulations as well as APIs, with products marketed in more than 50 countries. Key international markets include the United States, Canada and Brazil, while its domestic portfolio covers areas such as oncology, cardiology, diabetology and other specialty therapies.

NATCO places significant emphasis on research and development, particularly in complex molecules, high-potency APIs, peptides and advanced drug-delivery technologies. As of FY2026, the company had two R&D centres and around 500 researchers and scientists. Its agrochemical business provides crop-health solutions, including pesticides, bio-stimulants and growth promoters.

Overall, NATCO Pharma’s business model is built around niche products, vertical integration, strong R&D capabilities and global pharmaceutical markets, with the objective of developing and supplying specialised medicines and crop-health solutions

Object of the Issue :
  • Pre-payment or repayment of all or a portion of certain outstanding borrowings availed by the Company.
  • Funding a portion of the expenditure towards research and development initiatives of the Company, including funding costs of employees in our research and development team.
  • General Corporate Purposes.

Read also: Upcoming Rights Issue

Natco Pharma Rights issue Review :

Rights Issue Review Meter
0/100
Loading…

Based On Financial Overview

Natco Pharma Rights issue 2026 Details :

Event NameDetails
Issue Open :October 12, 2026
Issue Close :October 22, 2026
Record Date :October 01, 2026
Issue Size :₹1279.36 Cr
Face Value :₹2 per share
Price Band :₹750 per share
Listing On :BSE, NSE
Shares Offer :1,70,58,082
Ratio :2:21
Important Link :LOF

Read also: Upcoming Buyback Shares

Natco Pharma Rights issue 2026 Dates :

ActivityDates
Last Date to Buy Share :September 30, 2026
Record Date :October 01, 2026
Bid Open Date :October 12, 2026
Rights Entitlements :October 16, 2026
Bid Close Date :October 22, 2026
Allotment Date :October 23, 2026
Credit Date :October 26, 2026
Listing Date :October 27, 2026

Company Financial (in Cr):

YearRevenueExpensePAT
2026₹4078.30₹2707.00₹1371.90
2025₹4492.60₹4488.60₹1883.40
2024₹4007.30₹2525.40₹1388.30

Read also: Upcoming NCD Issue

How to apply Rights Issue :
  • Visit the registrar’s website.
  • Go to the ‘Rights Issue’ section.
  • Select Rights Issue from the dropdown.
  • Enter Demat Account Number.
  • Fill the online application form.
  • Validate and submit the application.
Registrar of the Rights Issue :
KFin Technologies Limited
Address: Selenium Tower-B,
Plot No. 31 & 32 Gachibowli
Financial District, Nanakramguda,
Serilingampally Hyderabad – 500 032,
Telangana, India.
Tel: +91 40 6716 2222/ 1800 309 4001
E-mail: [email protected]
Investor Grievance ID: [email protected]
Website: www.kfintech.com
Company Address :
Natco Pharma Limited
‘NATCO House’, Road No. 2,
Banjara Hills, Hyderabad – 500034,
Telangana, India
Tel: +91 40 2354 7532
E-mail: [email protected]
Website: www.natcopharma.co.in

Disclaimer: Stock Market Investments are Subject to Market risks, read all scheme Related Document Carefully Before Investing.

Natco Pharma Rights Issue 2026 Details

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top